Side-by-side · Research reference
AOD-9604vsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed10/47 cited
BFDA-ApprovedVerified27/68 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
AOD-9604
Tesamorelin
Primary target
β3-adrenergic receptor (proposed)Ng 2008
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
No GH-axis or IGF-1 feedback
Yes — physiological pulsatility preserved
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
AOD-9604
Tesamorelin
Standard dose
250–300 mcg / dayHeffernan 2001
Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.
2 mg / dayEGRIFTA® (tesamorelin for inje 2010
FDA-approved protocol.
Frequency
Once daily, fasted
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Lower / starter dose
150 mcg / day
1 mg / dayFalutz 2010
1 mg still produces significant IGF-1 elevation.
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2008
RCT / FDA-approvedFalutz 2007Falutz 2010
Duration
8–12 weeks per cycle
12–52 weeks
VAT returns within months of stopping.
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
Empty stomach, pre-sleep preferred
Half-life
~30 min plasma
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
03Metabolic / Fat Loss Evidence
Parameter
AOD-9604
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
AOD-9604
Tesamorelin
Injection site reaction
Mild erythema
Erythema, pruritus, redness (common)
GI symptoms
Rare mild nausea
Nausea, diarrhea (mild, transient)
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
IGF-1 elevation
None — designed to lack GH-axis activityHeffernan 2001
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
AOD-9604
Tesamorelin
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality